AU750295B2 - Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging - Google Patents

Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging Download PDF

Info

Publication number
AU750295B2
AU750295B2 AU72758/98A AU7275898A AU750295B2 AU 750295 B2 AU750295 B2 AU 750295B2 AU 72758/98 A AU72758/98 A AU 72758/98A AU 7275898 A AU7275898 A AU 7275898A AU 750295 B2 AU750295 B2 AU 750295B2
Authority
AU
Australia
Prior art keywords
leu
trp
val
phe
hemoglobin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU72758/98A
Other languages
English (en)
Other versions
AU7275898A (en
Inventor
Daniel H. Doherty
Christopher B. Glascock
Douglas D. Lemon
Antony J Mathews
John S. Olson
Michael J. Weickert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Biotech Technology SARL
William Marsh Rice University
Original Assignee
Baxter Biotech Technology SARL
William Marsh Rice University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Biotech Technology SARL, William Marsh Rice University filed Critical Baxter Biotech Technology SARL
Publication of AU7275898A publication Critical patent/AU7275898A/en
Assigned to WILLIAM MARSH RICE UNIVERSITY, RBHI Acquisition Corporation reassignment WILLIAM MARSH RICE UNIVERSITY Alteration of Name(s) of Applicant(s) under S113 Assignors: SOMATOGEN, INC., WILLIAM MARSH RICE UNIVERSITY
Assigned to BAXTER BIOTECH TECHNOLOGY S.A.R.L., WILLIAM MARSH RICE UNIVERSITY reassignment BAXTER BIOTECH TECHNOLOGY S.A.R.L. Alteration of Name(s) of Applicant(s) under S113 Assignors: RBHI Acquisition Corporation, WILLIAM MARSH RICE UNIVERSITY
Application granted granted Critical
Publication of AU750295B2 publication Critical patent/AU750295B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU72758/98A 1997-05-02 1998-05-01 Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging Ceased AU750295B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4536497P 1997-05-02 1997-05-02
US60/045364 1997-05-02
US5798697P 1997-09-05 1997-09-05
US60/057986 1997-09-05
PCT/US1998/008861 WO1998050430A2 (en) 1997-05-02 1998-05-01 Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging

Publications (2)

Publication Number Publication Date
AU7275898A AU7275898A (en) 1998-11-27
AU750295B2 true AU750295B2 (en) 2002-07-11

Family

ID=26722688

Family Applications (1)

Application Number Title Priority Date Filing Date
AU72758/98A Ceased AU750295B2 (en) 1997-05-02 1998-05-01 Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging

Country Status (7)

Country Link
US (2) US6455676B1 (OSRAM)
EP (1) EP0979279B1 (OSRAM)
JP (2) JP4512673B2 (OSRAM)
AU (1) AU750295B2 (OSRAM)
CA (1) CA2299049C (OSRAM)
DE (1) DE69839263T2 (OSRAM)
WO (1) WO1998050430A2 (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5099951B2 (ja) 1999-11-12 2012-12-19 バクスター・インターナショナル・インコーポレイテッド 副作用が減少されたヘモグロビン組成物
CA2467245A1 (en) * 2001-12-06 2003-06-19 Duke University Prevention of flap necrosis in plastic surgery
DE10224750A1 (de) 2002-06-04 2003-12-24 Fresenius Medical Care De Gmbh Vorrichtung zur Behandlung einer medizinischen Flüssigkeit
US20070166792A1 (en) * 2004-09-15 2007-07-19 Olson John S Increasing hemoglobin and other heme protein production in bacteria by co-expression of heme transport genes
US7642233B2 (en) * 2004-09-15 2010-01-05 William Marsh Rice University Enhancing recombinant hemoglobin production by co-expression with alpha hemoglobin stabilizing protein
WO2006031840A2 (en) * 2004-09-15 2006-03-23 William Marsh Rice University Increasing the stability of recombinant adult human apohemoglobin
US7935074B2 (en) 2005-02-28 2011-05-03 Fresenius Medical Care Holdings, Inc. Cassette system for peritoneal dialysis machine
US20060195064A1 (en) * 2005-02-28 2006-08-31 Fresenius Medical Care Holdings, Inc. Portable apparatus for peritoneal dialysis therapy
US8197231B2 (en) 2005-07-13 2012-06-12 Purity Solutions Llc Diaphragm pump and related methods
CN101460473A (zh) * 2006-04-03 2009-06-17 药物热化学品公司 热提取方法和产物
US8404631B2 (en) 2006-05-22 2013-03-26 The Regents Of The University Of California Compositions and methods for the delivery of oxygen
US7905990B2 (en) 2007-11-20 2011-03-15 Ensyn Renewables, Inc. Rapid thermal conversion of biomass
US8192401B2 (en) 2009-03-20 2012-06-05 Fresenius Medical Care Holdings, Inc. Medical fluid pump systems and related components and methods
EP2453946B1 (en) 2009-07-15 2013-02-13 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems
US8720913B2 (en) * 2009-08-11 2014-05-13 Fresenius Medical Care Holdings, Inc. Portable peritoneal dialysis carts and related systems
US8499702B2 (en) 2010-07-15 2013-08-06 Ensyn Renewables, Inc. Char-handling processes in a pyrolysis system
DE102010053973A1 (de) 2010-12-09 2012-06-14 Fresenius Medical Care Deutschland Gmbh Medizinisches Gerät mit einer Heizung
EP2654825B1 (en) 2010-12-20 2017-08-02 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US9624915B2 (en) 2011-03-09 2017-04-18 Fresenius Medical Care Holdings, Inc. Medical fluid delivery sets and related systems and methods
EP3006059B1 (en) 2011-04-21 2017-09-27 Fresenius Medical Care Holdings, Inc. Medical fluid pumping systems and related devices and methods
US9186449B2 (en) 2011-11-01 2015-11-17 Fresenius Medical Care Holdings, Inc. Dialysis machine support assemblies and related systems and methods
EP2776047A4 (en) * 2011-11-07 2015-07-22 Gen Hospital Corp TREATMENT OF ERYTHROCYTES
US9109177B2 (en) 2011-12-12 2015-08-18 Ensyn Renewables, Inc. Systems and methods for renewable fuel
US9610392B2 (en) 2012-06-08 2017-04-04 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US9500188B2 (en) 2012-06-11 2016-11-22 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
FR3002146B1 (fr) * 2013-02-15 2016-03-04 Hemarina Utilisation d'hemoglobine d'annelides pour traiter les cancers
US9561323B2 (en) 2013-03-14 2017-02-07 Fresenius Medical Care Holdings, Inc. Medical fluid cassette leak detection methods and devices
US10117985B2 (en) 2013-08-21 2018-11-06 Fresenius Medical Care Holdings, Inc. Determining a volume of medical fluid pumped into or out of a medical fluid cassette
US10752672B1 (en) * 2019-02-01 2020-08-25 Cheer Global Limited Recombinant hemoglobins and methods of preparation and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028588A (en) * 1987-05-16 1991-07-02 Somatogenetics International, Inc. Blood substitutes
WO1997004110A1 (en) * 1995-07-14 1997-02-06 Somatogen, Inc. Methods for increasing protein expression
WO1997015591A1 (en) * 1995-10-23 1997-05-01 Rice University Hemoglobin mutants that reduce heme loss

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022849A (en) * 1987-05-16 2000-02-08 Baxter Biotech Technology Saarl Mutant recombinant hemoglobins containing heme pocket mutations
US5449759A (en) 1987-05-16 1995-09-12 Somatogen, Inc. Hemoglobins with intersubunit desulfide bonds
US5599907A (en) 1989-05-10 1997-02-04 Somatogen, Inc. Production and use of multimeric hemoglobins
US5844090A (en) 1994-05-09 1998-12-01 Somatogen, Inc. Modified hemoglobin-like compounds
US5545727A (en) 1989-05-10 1996-08-13 Somatogen, Inc. DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
US5173426A (en) * 1989-10-06 1992-12-22 Yale University DNAs encoding genetically engineered low oxygen affinity mutants of human hemoglobin
EP0719284A1 (en) 1993-09-14 1996-07-03 Medical Research Council Improvements in or relating to haemoglobin
US5665869A (en) 1993-11-15 1997-09-09 Somatogen, Inc. Method for the rapid removal of protoporphyrin from protoporphyrin IX-containing solutions of hemoglobin
US5843888A (en) * 1995-05-01 1998-12-01 Carnegie Mellon University Low oxygen affinity mutant hemoglobin
WO1997023631A2 (en) * 1995-12-22 1997-07-03 Somatogen, Inc. Globins containing binding domains

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028588A (en) * 1987-05-16 1991-07-02 Somatogenetics International, Inc. Blood substitutes
WO1997004110A1 (en) * 1995-07-14 1997-02-06 Somatogen, Inc. Methods for increasing protein expression
WO1997015591A1 (en) * 1995-10-23 1997-05-01 Rice University Hemoglobin mutants that reduce heme loss

Also Published As

Publication number Publication date
WO1998050430A2 (en) 1998-11-12
AU7275898A (en) 1998-11-27
CA2299049C (en) 2008-07-15
US7049406B2 (en) 2006-05-23
JP2008194051A (ja) 2008-08-28
CA2299049A1 (en) 1998-11-12
US6455676B1 (en) 2002-09-24
JP4512673B2 (ja) 2010-07-28
EP0979279A2 (en) 2000-02-16
EP0979279B1 (en) 2008-03-19
DE69839263T2 (de) 2009-04-30
WO1998050430A3 (en) 1999-04-01
JP4399634B2 (ja) 2010-01-20
US20030017537A1 (en) 2003-01-23
DE69839263D1 (de) 2008-04-30
JP2002507115A (ja) 2002-03-05

Similar Documents

Publication Publication Date Title
US6455676B1 (en) Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging
US5801019A (en) DNA encoding fused alpha-beta globin pseuodimer and production of pseudotetrameric hemoglobin
US6184356B1 (en) Production and use of multimeric hemoglobins
US6828125B1 (en) DNA encoding fused di-alpha globins and use thereof
AU715914B2 (en) Globins containing binding domains
EP0832228B1 (en) Modified hemoglobin-like compounds and methods of purifying same
CA2791122C (en) Methods for preparing peg-hemoglobin conjugates using reduced reactant ratios
EP1950298A2 (en) Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging
CA2618690A1 (en) Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging
US6171826B1 (en) Methods of controlling beta dimer formation in hemoglobin
WO1997023631A2 (en) Globins containing binding domains
US6150506A (en) Modified hemoglobin-like compounds and methods of purifying same

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Free format text: BAXTER BIOTECH TECHNOLOGY SARL; WILLIAM MARSH RICE UNIVERSITY

FGA Letters patent sealed or granted (standard patent)